Gillian Morgan
About
In The Last Decade
Gillian Morgan
31 papers receiving 849 citations
Peers
Comparison fields: 5 of 64
- Immunology 442
- Public Health, Environmental and Occupational Health 239
- Molecular Biology 210
- Radiology, Nuclear Medicine and Imaging 204
- Epidemiology 199
Countries citing papers authored by Gillian Morgan
This map shows the geographic impact of Gillian Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gillian Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gillian Morgan more than expected).
Fields of papers citing papers by Gillian Morgan
This network shows the impact of papers produced by Gillian Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gillian Morgan. The network helps show where Gillian Morgan may publish in the future.
Co-authorship network of co-authors of Gillian Morgan
This figure shows the co-authorship network connecting the top 25 collaborators of Gillian Morgan. A scholar is included among the top collaborators of Gillian Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gillian Morgan. Gillian Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 7 | |
| 3 | 5 | |
| 4 | Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone | 1 |
| 5 | Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) | 4 |
| 6 | 74 | |
| 7 | Characterization of a recombinant Onchocerca volvulus antigen (Ov33) produced in yeast. | 13 |
| 8 | 117 | |
| 9 | 8 | |
| 10 | 140 | |
| 11 | 56 | |
| 12 | 10 | |
| 13 | 9 | |
| 14 | 16 | |
| 15 | 12 | |
| 16 | 8 | |
| 17 | 17 | |
| 18 | 9 | |
| 19 | 131 | |
| 20 | 16 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.